FDA is about to inspect out contract manufacturer’s Tylosin in NingXia, China during July 28th to October 1st.
2020 is an unusual year, with sudden COVID-19 quickly sweeping the globe. China have adopted strict prevention and control measures and stubbornly resisted the COVID-19. At present, the spread of the COVID-19 in China has been effectively controlled. The factory has resumed work and production, and our lives have gradually returned to normal.
We are always concerned about the development of the global epidemic. As an international company, we hope to contribute to the people who are suffering from the epidemic in the world.
Pharmax supplies the following qualified products to the global market, which are produced by the leading manufacturer in China with CE certificate available.
Medical masks N95, KN95, 3M, disposable medical masks, disposable civilian masks; medical isolating masks; medical goggles; medical protective clothing; medical protective gowns; medical non-contact thermometers; nitrile gloves;
If you are looking for these products, please feel free to contact us. We will provide you with the best supplies and services!
Contact Person: Gerry Tian
CPHI Frankfurt 2019 – Our 20th Time To Attend The World Largest Exhibition For Pharmaceutical Industry
Pharmax as an Exhibitor had just finished its 20th show at CPHI Worldwide in Frankfurt, with more than 200 visitors from over 40 countries visited us this year, we would like to thank all of our associated customers, friends from the industry for visiting us for friendship and partnership，which bring alot of exciting opportunities.
Pharmax will continue our best support and services to provide the complete strategic sourcing solution for our customers.
We care about healthier lives, and we are here to help every step of the way.
Focusing on the development of the global health industry, in order to better serve and meet the needs of customers, and expand our business in the global market, we are pleased to announce that Pharmax acquired a US dietary supplement manufacturer in July 2019 –Action labs.
Action labs is located in California, USA. Since its establishment in 1964, it has been consistently providing the highest quality health products to consumers around the world for 55 years. We bring sympathy, formality, responsibility and true values to everything we do. Action labs’ own brand, Sentinel, has 155 products, is well known in pharmacies across Southern California, and has been trusted by consumers in many countries and areas for many years.
Combining the most advanced knowledge in nutrition science with the finest quality ingredients, we have consistently provided consumers with supplements of unsurpassed quality and value.
We are actively seeking distribution partners globally. Your inquiry will be highly welcomed and we would love to have the opportunity to work with you.
CPHI Worldwide 2019
05-07 November 2019
Messe Frankfurt, Germany
Our booth number: 61B33
Supplyside West 2019
17&18 October 2019
Mandalay Bay, Las Vegas
Our booth number:1448
CPHI China 2019
June 18 – 20, 2019
Shanghai New Int’l Expo Centre (SNIEC), Shanghai, China
Welcome to visit us at our booth W2D30!
CPHI North America 2019
30 April-2 May 2019
Welcome to visit us at our stand 2107!
VIV ASIA 2019
13 March-15 March 2019
BITEC Bangkok, Thailand
Our stand number: H106.201
International Production & Processing Expo (IPPE) 2019
Georgia World Congress Center, Atlanta, Georgia USA
Our booth number: A2219
We are proud to announce that our Moxidectin project has achieved a new milestone:
The New Drug Application (NDA) of Moxidectin for treatment of the orphan disease river blindness has been approved by the US FDA this week. The product was developed by Medicines Development for Global Health, an independently funded biopharmaceutical company that focuses exclusively on neglected diseases, while the Moxidectin API is supplied by Pharmax and manufactured by Livzon Group. The successful approval of the New Drug Application represents a joint success of MDGH, Pharmax and Livzon who have been working hard together for years, and the first approval of moxidectin for use in humans.
MDGH received funding for this project from the Global Health Investment Fund, and plans to supply Moxidectin to those in need, mainly in Africa. We believe the new moxidectin product will bring health benefits to people in both developing and developed world.